

E-REFERENCES

- e1. Rodriguez-Sanchez E, Mora-Simon S, Patino-Alonso MC, et al. Prevalence of cognitive impairment in individuals aged over 65 in an urban area: DERIVA study. *BMC Neurol* 2011;11:147.
- e2. Saxton J, Snitz BE, Lopez OL, et al. Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia. *J Neurol Neurosurg Psychiatry* 2009;80:737–743.
- e3. Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. *Neurology* 2004;63:1882–1891.
- e4. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. *Ann Intern Med* 2008;148:427–434.
- e5. Roberts RO, Knopman DS, Mielke MM, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. *Neurology* 2014;82:317–325.
- e6. Monastero R, Palmer K, Qiu C, Winblad B, Fratiglioni L. Heterogeneity in risk factors for cognitive impairment, no dementia: population-based longitudinal study from the Kungsholmen Project. *Am J Geriatr Psychiatry* 2007;15:60–69.
- e7. Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder: the Cache County Study. *Neurology* 2006;67:229–234.
- e8. Lopez OL, Becker JT, Chang YF, et al. Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. *Neurology* 2012;79:1599–1606.
- e9. Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. *Neurology* 2012;78:91–101.
- e10. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med* 2005;352:2379–2388.
- e11. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. *Neurology* 2009;72:1555–1561.
- e12. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. *Neurology* 2004;63:651–657.
- e13. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. [Erratum appears in *Neurology* 2010;75:1485]. *Neurology* 2008;70:2024–2035.
- e14. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study.[see comment][erratum appears in *Lancet Neurol* 2007;6:849]. *Lancet Neurol* 2007;6:501–512.
- e15. Desideri G, Kwik-Urbe C, Grassi D, et al. Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. *Hypertension* 2012;60:794–801.
- e16. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. *PLoS ONE* 2010;5:e12244.
- e17. Thal LJ, Ferris SH, Kirby L, et al.; on behalf of the Rofecoxib Protocol 078 study group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. *Neuropsychopharmacology* 2005;30:1204–1215.

- e18. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. *Arch Neurol* 2012;69:1420–1429.
- e19. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. *Am J Psychiatry* 2001;158:1517–1519.
- e20. Dubois B, Zaim M, Touchon J, et al. Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer's disease. *J Alzheimers Dis* 2012;29:527–535.
- e21. Naeini AM, Elmadfa I, Djazayeri A, et al. The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: a double-blind, randomized, placebo-controlled trial. *Eur J Nutr* 2014;53:1255–1262.
- e22. Nagamatsu LS, Handy TC, Hsu CL, Voss M, Liu-Ambrose T. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment.[Erratum appears in *Arch Intern Med* 2013;173:1477]. *Arch Intern Med* 2012;172:666–668.
- e23. Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. *PLoS ONE* 2013;8:e61483.
- e24. Kinsella GJ, Mullaly E, Rand E, et al. Early intervention for mild cognitive impairment: a randomised controlled trial. *J Neurol Neurosurg Psychiatry* 2009;80:730–736.
- e25. Kinsella GJ, Ames D, Storey E, et al. Strategies for improving memory: a randomized trial of memory groups for older people, including those with mild cognitive impairment. *J Alzheimers Dis* 2016;49:31–43.
- e26. Tsolaki M, Kounti F, Agogiatou C, et al. Effectiveness of nonpharmacological approaches in patients with mild cognitive impairment. *Neurodegener Dis* 2011;8:138–145.
- e27. Nakatsuka M, Nakamura K, Hamanosono R, et al. A cluster randomized controlled trial of nonpharmacological interventions for old-old subjects with a Clinical Dementia Rating of 0.5: The Kurihara Project. *Dement Geriatr Cogn Dis Extra* 2015;5:221–232.
- e28. Lam LC, Chan WC, Leung T, Fung AW, Leung EM. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PLoS ONE* 2015;10:e0118173.
- e29. Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW, Alzheimer's Disease Neuroimaging I. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. *J Int Neuropsychol Soc* 2014;20:836–847.
- e30. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. *JAMA* 2014;312:2551–2561.
- e31. Association AM. MLN Matters News Flash: Annual wellness visit (AWV), including personalized prevention plan services (PPPS). 2009. Available at: <http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM7079.pdf>. Accessed January 19, 2013.
- e32. Lin JS, O'Connor E, Rossom RC, Perdue LA, Eckstrom E. Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2013;159:601–612.
- e33. Burke D, Sengoz A, Schwartz R. Potentially reversible cognitive impairment in patients presenting to a memory disorders clinic. *J Clin Neurosci* 2000;7:120–123.
- e34. Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. *Exp Gerontol* 2010;45:5–14.

- e35. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* 2012;367:795–804.
- e36. Ahmed AI, Driessen S, van Schendel FM. Role of plasma bilirubin as a biomarker for Alzheimer's disease: a retrospective cohort study. *J Am Geriatr Soc* 2014;62:398–399.
- e37. Ritchie C, Smailagic N, Noel-Storr AH, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev* 2014:CD008782.
- e38. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. *Ann Intern Med* 2008;148:379–397.
- e39. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. *Neurology* 1998;50:136–145.
- e40. Reisberg B, Ferris SH, Oo T, Franssen E. Staging: relevance for trial design in vascular burden of the brain. *Int Psychogeriatr* 2003;15 Suppl 1:231–239.
- e41. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. *Dement Geriatr Cogn Disord* 2005;20:120–132.
- e42. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. *CNS Neurosci Ther* 2013;19:745–752.
- e43. Birks J, Flicker L. Donepezil for mild cognitive impairment - art. no. CD006104. *Cochrane Database of Systematic Reviews* 2006:6104.
- e44. Peters ME, Rosenberg PB, Steinberg M, et al. Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study. *Am J Geriatr Psychiatry* 2012;20:416–424.
- e45. Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. *Neurology* 2004;62:1199–1201.
- e46. Van der Mussele S, Marien P, Saerens J, et al. Behavioral syndromes in mild cognitive impairment and Alzheimer's disease. *J Alzheimers Dis* 2014;38:319–329.
- e47. Apostolova LG, Di LJ, Duffy EL, et al. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. *Dement Geriatr Cogn Disord* 2014;37:315–326.
- e48. Peters ME, Rosenberg PB, Steinberg M, et al. Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study. *Am J Geriatr Psychiatry* 2013;21:1116–1124.
- e49. Ismail Zea. A systematic review and meta-analysis for the prevalence of depression in mild cognitive impairment. *Alzheimers Dement* 2015;11:516–517.
- e50. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010;63:834–840.